Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

GROUNDWORK BIOAG’S GLOBAL COMMERCIAL BUSINESS EXPANDS TO CHINA

Groundwork BioAg

As part of its steady global expansion, Groundwork BioAg opened a representative office in China to serve one of the world’s leading agriculture markets, with approximately 127 million hectares of harvested farm cropland. The company’s flagship BioPlatform - Rootella ® - will be available to farmers across four of the world’s major agricultural markets: the United States, Brazil, India, and now China. “As food demands continue to intertwine with climate pressures on a global scale, we look forward to helping Chinese farmers reduce the negative impact of synthetic fertilizers, particularly phosphorus, while establishing more resilient crop production and permanent carbon sequestration across millions of hectares in China,” said Dr. Yossi Kofman, co-founder and CEO of Groundwork BioAg. “As the ‘Queen of Biologicals,’ highly concentrated mycorrhizal inoculants enable all other innovation to ensure conventional farmers can regenerate their soil, sequester carbon, and grow a bountiful, more sustainable harvest.” Located in the city of Sanya in the agricultural hub of Hainan Province, the representative office will act as Groundwork BioAg’s business center for customers and partners across China. Mr. Shu Yang, an experienced manager in agriculture and biologicals, will lead the office. The new business center will enable the company to help farmers enact China’s 14th Five-Year National Agriculture Green Development Plan. Announced in October of 2021, the Plan identified resource protection, pollution control, restoration of agricultural ecology, and the development of low-carbon agricultural industrial chains as key goals to be achieved by 2025. According to the FAO, China is among the world’s largest agricultural producers of cereals, cotton, fruit, and vegetables, and remains second only to the United States in corn production. Groundwork BioAg is the first mycorrhiza producer that can support large-scale agriculture based on its unique production capabilities. Applied on more than one million acres in 2021, Rootella is based on naturally robust strains of mycorrhizal fungi that are symbiotic with 90% of plant species, offering the most efficient and effective solution to diverse crops and growing areas. Kofman said, “China is a cornerstone of our global plan and critical to delivering on our promise to help reduce the impact of climate change while ensuring global food security.” Groundwork BioAg has established commercial operations across most of the world’s major agricultural markets, including the United States, Brazil, China, India, Canada, Europe, Ukraine, and New Zealand. In March, Groundwork BioAg® was named by Fast Company as one of the World’s Most Innovative Food Companies for 2022 for tackling grand challenges facing humankind today: food security, soil health, and climate change. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

April 20, 2022 06:30 AM Central Daylight Time

SC Johnson Chairman and CEO Welcomes Tanzanian President Hassan, Reaffirms Commitment to Helping Eradicate Malaria

SC Johnson

SC Johnson Chairman and CEO Fisk Johnson today welcomed Her Excellency Samia Suluhu Hassan, President of the United Republic of Tanzania, to Racine to discuss their shared commitment to eradicating malaria and to tour the company’s Center for Insect Science and Family Health, one of the world’s largest private, urban entomology research centers. Research from the Center helps SC Johnson in the development of its repellent and insecticide brands such as OFF! ® and Raid ®, as well as low-cost spatial repellent options for people who lack access to mosquito prevention tools. “Every minute, a child under five dies from malaria, most of whom are from Africa, and at SC Johnson, we are committed to sharing our expertise in insect science to help eradicate this tragic, yet preventable, disease,” said Fisk Johnson, Chairman and CEO of SC Johnson. “We are honored to welcome President Hassan and are grateful to work alongside the Tanzanian government and the greater East African Community toward our common goal of eliminating malaria.” Malaria is an illness caused by parasites which are spread to people through the bites of certain mosquitoes. Africa is home to 95% of malaria cases and 96% of deaths. Children under the age of five accounted for approximately 80% of deaths in the region, according to the World Health Organization. SC Johnson is in the process of developing and testing new, low-cost spatial repellent technologies that can be used by people who lack access to prevention tools in some of the world’s most vulnerable regions. These repellents are easy to use, do not require electricity or flame, and work continuously for up to 10 months. Large-scale clinical trials are underway in Kenya and have been completed in Indonesia and Peru. For more information on SC Johnson’s efforts to end malaria and create a healthier world, visit: https://www.scjohnson.com/en/a-healthier-world/it-takes-a-family-to-end-malaria About SC Johnson Founded in 1886 and headquartered in Racine, Wisconsin USA, SC Johnson believes that a more sustainable, healthier and transparent world that inspires people and creates opportunities isn't just possible - it's our responsibility. A heritage of innovation and bold, transparent decisions is why our high-quality products and iconic brands – including OFF! ® Raid ®, Glade ®, Windex ®, Scrubbing Bubbles ®, Ziploc ®, Mrs. Meyer’s Clean Day ®, method ®, Autan ®, Baygon ®, Mr Muscle ®, Duck ®, Lysoform ® and more – are in homes, schools and businesses in virtually every country worldwide. As a global, purpose-led company, we are committed to making the world a better place today and for future generations. That means relentlessly bringing our expertise in science, innovation and partnerships to bear on some of the world's most pressing environmental and health issues like reducing plastic waste and eradicating malaria. Around the world, we use our resources to unlock greater economic and educational opportunities for people and communities where access may be limited, but curiosity and potential are limitless. See how SC Johnson is a Family Company At Work For a Better World by visiting scjohnson.com or joining us on Facebook, Twitter, LinkedIn, Instagram and YouTube. Contact Details SC Johnson Global Corporate Communication +1 262-260-2440 GlobalPublicAffairs@scj.com Company Website https://www.scjohnson.com/

April 19, 2022 04:03 PM Eastern Daylight Time

Image

Genomic Life to Present at Business Group on Health’s Annual Conference

Genomic Life

Genomic Life, a leading genome benefit management company with a mission of providing innovative benefit services to employers, will present at the Business Group on Health’s annual conference. The Business Group on Health’s annual conference brings together experts and employers related to health benefits and health care policies. This year’s theme is “Collaborating on the Future of Health and Well-Being,” and will be held between April 19-21, 2022 at the Renaissance Nashville Hotel. The company has an over-arching goal of making affordable clinical-grade genetic testing available to everyone, genetic testing plays an essential role in managing proactive health, informing individuals of their health risks and pre-existing conditions they would not have known about otherwise. Genomic Life helps facilitate the most appropriate testing at the highest quality labs with access to clear results and expert genetic counseling. These services help patients and their physicians turn those genetic insights into precise and timely actions. On Tuesday, April 19, 2022, from 9 – 11 a.m. CDT, Genomic Life will host an invite-only breakfast event panel at the nearby historic Union Station Nashville Hotel. Guests can also join virtually via Zoom. The panel will be focused on the future of proactive health and the power of genetic testing, hosted and moderated by WKRN-TV News anchor Nikki Burdine of “Good Morning Nashville,” and will feature Genomic Life executives, Karen Ferrell, MBA (Chief Executive Officer); Randy Scott, PhD (Executive Co-Chairman); Tod Klingler, PhD (Head of Product and Innovation); Robert Green, MD, MPH (Medical and Clinical Advisor); and Noël Rihm Obourn (Chief Commercial Officer). “Health technology is accelerating at a rapid pace and employers are looking for innovative ways to keep their employees healthy and engaged,” said Genomic Life CEO Karen Ferrell. “We are working with employers to take the guesswork out of genetic testing and services and help individuals and their own physicians be proactive and precise about their health and well-being.” On Wednesday, April 20, 2022 from 2-2:30 p.m. CDT, Genomic Life Executive Co-Chair Randy Scott, PhD will present a breakout session titled “Innovations in Cancer Screening and Genetic Testing” at the Business Group on Health’s annual conference. The discussion will cover how employers can leverage the power of genetic testing, precision medicine and clinical policy to strengthen their overall benefit strategy. Dr. Scott will be joined by Scott Osler, Vice President of Employer Partnerships at Grail, Inc. “Being in the field of genomics for more than 30 years, including leading the development of two revolutionary cancer diagnostic tests, I have learned a lot about how a preventive approach to healthcare can truly make a difference,” said Dr. Scott. “Our team at Genomic Life is hard at work offering comprehensive genetic testing services that span a lifetime of health benefits. We look forward to helping anyone and everyone we can make proactive, personalized and precise healthcare choices that positively impact their lives.” Genomic Life currently offers three types of genetic screenings to unlock precise and relevant healthcare insights, before illness occurs: Genetic Health Screen (GHS): A 147 gene panel that includes genetic predispositions to specific serious illnesses (cancers, cardiac, neurology, and more). Pharmacogenomics (PGx) Screen: With 25 biomarkers, this screen highlights drug-gene interactions and efficacy, informing the patient and physician which prescriptions and dosages are optimal, which are harmful, and which aren’t likely to do anything at all. Carrier Screen: A 289 gene panel that identifies critical recessive traits for those who are focused on family planning. The results include details about hereditary diseases that can be passed on to offspring and may compromise pediatric health. The results are coordinated with one’s OB-GYN to help take actions to understand and mitigate risks. Additionally, genomic insights are pivotal in the diagnosis and treatment of cancer; Genomic Life’s Cancer Guardian solution works with cancer patients and their own oncology team to facilitate best practices, ensuring that cancer patients benefit from the most precise, genomically-informed treatments. To learn more about Genomic Life and these events, please visit: https://info.genomiclife.com/lp/nbgh/. ### About Genomic Life Founded in 2017, Genomic Life is a leading genome benefit management company making affordable, clinical-grade genetic testing available to everyone, with a mission to provide innovative benefit services to employers. Genomic Life is helping close the gap in healthcare by working directly with employers to provide access to affordable genetic testing services that will enable them to seek better medical care and fill in the technology, innovation and healthcare gaps missed by health insurance companies.For more information, visit https://genomiclife.com. About Business Group on Health Business Group on Health is the leading non-profit organization representing large employers’ perspectives on optimizing workforce strategy through innovative health, benefits and well-being solutions and on health policy issues. The Business Group keeps its membership informed of leading-edge thinking and action on health care cost and delivery, financing, affordability and experience with the health care system. Business Group members include 72 Fortune 100 companies as well as large public-sector employers, who collectively provide health and well-being programs for more than 60 million individuals in 200 countries. For more information, visit www.businessgrouphealth.org. Contact Details The Hoyt Organization Cinnamon Thompson +1 310-373-0103 cthompson@hoytorg.com Company Website https://genomiclife.com/

April 19, 2022 09:00 AM Central Daylight Time

Image

TONGRENTANGCM (Hong Kong Stock Exchange: 03613) 2021 performance bucks the trend and rises Net profit reached HK$651 million, overseas business revenue increased by 30.6%

Beijing Tongrentang Chinese Medicine Co., Ltd.

HONG KONG SAR - Media OutReach - 19 April 2022 - Traditional Chinese medicine has played an important role in the prevention and control of the epidemic in recent years. In addition, the national policy has vigorously promoted the development of the industrial chain. Tongrentang, which has a brand history of more than 300 years, is actively seizing development opportunities. TONGRENTANGCM (03613), which is rooted in the Hong Kong market, revealed in its recently announced 2021 annual results announcement that its net profit reached HK$651 million, with its overseas market business revenue growing at a rapid rate of 30.6% against the trend. Both local and overseas business revenue in Hong Kong maintained high growth under the epidemic, demonstrating a stable business strategy and strong overseas development potential. The performance bucked the market and rose Strong internal and external operations The overall revenue of TONGRENTANGCM in 2021 was HK$1.556 billion, an increase of 18.3% over the same period last year, and its annual net profit reached HK$651 million, a year-on-year increase of 14.7%, of which the net profit attributable to shareholders of the listed company was HK$607 million, a year-on-year increase of 12.1%. The performance of the Hong Kong market maintained a steady growth rate, with a total revenue of HK$688 million, an increase of 26% over the previous year. The business in the overseas market achieved rapid growth, up 30.6% despite the raging global epidemic, fully demonstrating the capabilities of TONGRENTANGCM in the face of difficulties. It also reflects the potential of the Chinese medicine market overseas and in the future. Turning Crisis into Opportunity Innovating the TCM Services for International Markets Riding on the state's policies on traditional Chinese medicine business, TONGRENTANGCM seized the development opportunities, turned the crisis into an opportunity under the influence of the global epidemic, and actively explored the new ways in which traditional Chinese medicine can serve the world. Specialized in the prevention and control of the COVID19 epidemic, Tongrentang prescribed various TCM treatment programs and products for the prevention and control of the epidemic, successfully establishing a good brand reputation and image for overseas potential customers. In 2021, TONGRENTANGCM has won a number of international awards, including the 2021 Chinese Medicine Industrial Award issued by Chinese Medicine Industry Council of Australia Ltd., and the 2021 Most Influential Brand in Asia: Traditional Chinese Medicine Most Trustworthy Brand by Influential Brands, etc. Many international honors have certified the credibility and accreditation of Tongrentang's traditional Chinese medicine business overseas, which greatly enhances the confidence of foreign consumers in the brand. Fulfill social corporate responsibility Continue to contribute to epidemic prevention TONGRENTANGCM has always adhered to the corporate spirit of "Nurturing kindness and virtue, Preserving tranquility and wellness”", and have made various contributions to the society before and during the epidemic in Hong Kong. On March 2 this year, 100,000 boxes of Huoxiang Zhengqi Pian (lophanthus antifebrile tablet) worth nearly 6 million Hong Kong dollars were donated to the Hong Kong Special Administrative Region, and successively TONGRENTANGCM also donated a total value of nearly HK$700,000 of epidemic prevention and control materials, including COVID-19 Antigen Rapid Test kits, N95 anti-epidemic masks, Tongrentang traditional Chinese medicine, health drugs and food to various social welfare organizations, including Hong Kong's century-old charity organization Sik Sik Yuen, Self Help Group For the Brand Damaged, Neuro United, The Hong Kong Stroke Association, providing the social groups and the general public with the much needed anti-epidemic and health care assistance. Tongrentang donated 100,000 boxes of lophanthus antifebrile tablets worth nearly HK$6 million to the Hong Kong Special Administrative Region. Meanwhile, TONGRENTANGCM also took the initiative to offer purchase discounts on anti-epidemic products to many Chinese institutions and launched a special package of Ganoderma lucidum spore powder capsules to provide the public with more choices of anti-epidemic products. Currently, it is also planning to donate Antigen Rapid Test kits for COVID-19 to many nursing homes in Hong Kong, so that the elderly with limited mobility can also conduct self-testing, and further checking the epidemic situation in Hong Kong. Website︰ https://cm.tongrentang.com/ This press release is issued by Beijing Tongrentang Chinese Medicine Co., Ltd. Contact Details Beijing Tongrentang Chinese Medicine Co., Ltd. brandtrt@tongrentangcm.com

April 19, 2022 09:00 AM Eastern Daylight Time

Image

News Release

National Marrow Donor Program®/Be The Match® Implements Comcast Business Wavelength Services to Help Match Cancer Patients With Donors

Comcast Twin Cities

Comcast Business today announced that it is providing the National Marrow Donor Program® (NMDP)/Be The Match®, the leading global leader working to save lives through cellular therapy with a 10 Gbps optical wavelength service. The high-capacity, low-latency network solution will help Be The Match strengthen network performance, keeping its clients and employees connected, and in turn helping to ensure that transplant donors are connected to patients in need. Be The Match provides patients access to more than 39 million donors worldwide who step up to donate their marrow or blood stem cells. By connecting patients with donors and delivering life-saving cells to them, Be The Match provides cures to patients with life-threatening blood cancers and 75 blood diseases. The organization continues to lead the way in developing new cellular therapies, and in improving transplant accessibility and outcomes. Conducting this life-saving research while supporting and connecting patients to the resources they need requires a high-bandwidth, low-latency network connection. “Our network is becoming more critical, especially as we move to the cloud. If our systems aren’t available, people’s lives could be at stake,” said Robert Hanson, Vice President, Information Security, Infrastructure and Architecture, at Be The Match. “Comcast Business’ network performance has been seamless.” Comcast Business Wavelength Services deliver superior connectivity over a dense wave division multiplexing (DWDM) optical transport network with high levels of performance. Wavelength technology provides users with the ability to transport both Ethernet and non-Ethernet protocols. The point-to-point optical fiber network helps deliver data across several of Be The Match’s locations, including its headquarters in Minneapolis, its branch offices and its data center location. Since implementing Comcast Business’ services, Be The Match has been able to continue supporting patients across its various locations without concerns over network connectivity. Additionally, the reliable and fast network connections help position the organization for rising bandwidth demands and network growth, setting it up to serve its clients into the future. “To stay swift and competitive, businesses across industries continue to incorporate cloud and data center operations into their daily functions. With this will come the need for networking technology that can not only support the shifts in business today, but the continually rising bandwidth needs that the future demands,” said Wolfgang Lewis, Vice President for Comcast Business, Twin Cities Region. “Comcast Business is proud to support National Marrow Donor Program/Be The Match with its network services and do its part in making a difference in our communities.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About National Marrow Donor Program®(NMDP)/Be The Match® The National Marrow Donor Program®(NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With more than 30 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®(Center for International Blood and Marrow Transplant Research®)—a collaboration with Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care. Contact Details Comcast Jill Hornbacher Jill_Hornbacher@comcast.com Finn Partners Chloe Huard chloe.huard@finnpartners.com Company Website https://twincities.comcast.com/

April 19, 2022 08:00 AM Eastern Daylight Time

G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

G Medical Innovations Holdings

TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investor warrants to purchase up to an aggregate of 6,250,000 ordinary shares. The purchase price for one ordinary share and one warrant to purchase one ordinary share is $1.50. The warrants have an exercise price of $1.50 per ordinary share, will be immediately exercisable, and will expire five years from issuance. A.G.P./Alliance Global Partners is acting as the sole placement agent for offering. The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the offering for the repayment of existing debt and working capital purposes. The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions. The Company also has agreed that certain warrants to purchase an aggregate of 2,400,000 ordinary shares of the Company that were issued to the investor in February 2022 will be amended to have a reduced exercise price of $1.50 per ordinary share. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 30 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

April 18, 2022 07:00 AM Eastern Daylight Time

AmeriLife’s Senior Market Advisors Partners With Buffalo Health Advisors

AmeriLife

Senior Market Advisors (SMA), one of the fastest growing field marketing organizations (FMO) in the insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Buffalo Health Advisors, one of the top health insurance distributors in Tennessee that specializes in Medicare Advantage, Medicare Supplement and PDP solutions, as well as health insurance for the under-65 market. The partnership brings more than 450 field agents in Buffalo’s network under the SMA banner, while also expanding SMA’s geographical footprint in the southeast United States. Per the agreement, terms of the deal were not disclosed. “Buffalo Health Advisors is a dynamic and exciting force in our industry,” said Andy Watkins, vice president of sales and agency development, East region, for Senior Market Advisors. “Senior Market Advisors and AmeriLife are excited to start leveraging our multiple synergies to promote its overall growth and the betterment of our Medicare beneficiaries.” “Simply, Buffalo Health Advisors has always been about bringing the very best marketing strategies, business services and fun to our agent partners,” added Joshua Borders, owner and vice president of sales for Buffalo Health Advisors. “We’re very excited to partner with SMA and AmeriLife to unlock amazing new tools, technologies and relationships for our partners and clients. We’ve only just begun!” While Buffalo Health Advisors will continue to operate as a stand-alone organization in SMA’s downline, it will consolidate its office resources at SMA’s Nashville, Tennessee, headquarters. Likewise, Borders will continue to oversee Buffalo’s day-to-day operations, reporting to SMA’s Vice President of Corporate Operations Victoria Buckman. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 insurance agents and advisors, more than 50 marketing organizations, and 50 insurance agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About Senior Market Advisors Senior Market Advisors (SMA) has been people over profits since 2007, by hard work and a commitment to “doing right” by the consumer. We have certainly knocked on our fair share of doors. We know the grit and determination involved in becoming a career agent. And as a result, we have become one of the fastest growing FMOs, doubling our business each year for the past five years. For more information, visit us online at SeniorMarketAdvisors.com. Contact Details AmeriLife Communications Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Senior Market Advisors Communications Sarah Smith ssmith@seniormarketadvisors.com AmeriLife Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

April 14, 2022 02:00 PM Eastern Daylight Time

Industrial Defender Unveils New Standalone OT Vulnerability Management Solution, Immunity by ID™

Industrial Defender

Industrial Defender, the leader in operational technology (OT) security, today announced the launch of Immunity by ID™, a new cloud-based offering that helps industrial security teams turn their OT asset inventory information into a risk-based vulnerability management program. The product is offered as a standalone solution or as an add-on within the Industrial Defender platform. Using current OT hardware and software inventory information from an asset visibility tool, CMDB or spreadsheet, this vendor-agnostic solution generates a prioritized list of vulnerabilities based on asset criticality and risk level, along with applicable patching data, to help keep critical infrastructure secure in the face of global cybersecurity threats. Immunity by ID is up and running in a matter of days, allowing users to begin their vulnerability management program immediately, and simple, transparent pricing lets them easily scale a subscription as they mature. “With the looming threat of a global cyber war, critical infrastructure organizations of all sizes are looking for straightforward solutions that rapidly deliver actionable intelligence to help them protect their essential systems,” said Peter Lund, CTO at Industrial Defender. “We created this tool to help companies better utilize the asset information they already have that may be nothing more than a data dump right now. Unlike other OT vulnerability management offerings on the market, ours is powered by an anonymized cloud, so as soon as a vulnerability is published, you'll know whether a device is at risk without waiting for the next software update.” Industrial Defender will be offering a free 14-day trial of Immunity by ID to qualified users at North American and European critical infrastructure companies through the end of May to support their efforts to shore up cybersecurity defenses. For more information, visit https://www.industrialdefender.com/immunity-by-industrial-defender/. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

April 14, 2022 09:00 AM Eastern Daylight Time

PathPresenter Introduces ClinPx™ - A Clinical Enterprise Platform

PathPresenter

Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded from around the world – directly in Beaker. PathPresenter, the premier digital pathology platform for education and conferences with more than 40,000 users and 20+ institutional licenses, now presents to clinical users a best-in-class clinical enterprise platform, ClinPx. ClinPx is a custom, institution-branded, clinical enterprise platform that enables pathology consultations to be directly viewed and reported in your institution’s LIS through our proprietary backend HL7 messaging engine. It has inbuilt quality control (QC) ensuring whole slide images are of diagnostic quality and has the ability to integrate validated AI models into the scanner-agonistic viewer. ClinPx allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists as well as bidirectional communication channels for ordering stains and recuts. It also enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. This functionality brings the control and organization of the clinical workflow back to the end user. Our first pilot installation with The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) integrates ClinPx into Epic’s Beaker LIS, allowing pathologists at The Ohio State University to receive, view, and sign out cases uploaded from around the world directly in Beaker. “Our goal is to use ClinPix to augment OSU’s pathology clinical consultation capabilities globally. ClinPx has the ability to integrate with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate,” said Dr. Anil Parwani, vice chair of anatomic pathology at The Ohio State University College of Medicine. Rajendra Singh, co-founder of PathPresenter, added “ClinPX creates a solution to allow for the integration of digital pathology into existing workflows used by pathologists without disruption.” This platform is installed as a pilot project at The Ohio State University for potential expansion of its digital pathology consultation service. Dr. Parwani has no personal conflicts of interest to disclose. About PathPresenter PathPresenter is the world’s most widely used digital pathology platform, with a community of more than 40,000 users in 172 countries and 20+ institutional licenses. Our educational and conference module provides a seamless environment for pathologists, radiologists, clinicians, and life science researchers to use, share and collaborate with fellow clinicians throughout the world to learn, teach, present, perform research, and practice better medicine, while connecting industry to a global community of clinicians and researchers. Get started with PathPresenter, for free, at https://pathpresenter.net/. Our new ClinPX TM clinical enterprise platform helps hospitals and labs expand the reach of their clinical consultation (2 nd opinion) services globally, increase their efficiency, and optimize the user experience for both consulting pathologists and client pathologists. Through deep integration with the institution’s existing laboratory information system (LIS), consulting pathologists can receive, view, and sign out cases uploaded from around the world directly in the LIS. ClinPX allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists in addition to bidirectional communication channels for ordering stains and recuts. Further, it enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. Through a robust API, ClinPX integrates with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.net

April 13, 2022 11:00 AM Eastern Daylight Time

1 ... 187 188 189 190 191 ... 264